Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Sera Prognostics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Sera Prognostics wird ein Gewinn- und Umsatzwachstum von 0.2% bzw. 95.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 1.6% pro Jahr wachsen soll.

Wichtige Informationen

0.2%

Wachstumsrate der Gewinne

1.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.1%
Wachstumsrate der Einnahmen	95.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Sera Prognostics' PreTRM: A Speculative Buy In Women's Health

Mar 24

Sera Prognostics: The Pregnancy Company On A Hot Streak

Jan 10

Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?

Oct 03

We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth

Jun 15

We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate

Feb 16

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Nov 03

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Aug 10

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Jul 21

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Apr 06

We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Dec 15

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:SERA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	22	-35	N/A	N/A	1
12/31/2025	9	-31	N/A	N/A	2
12/31/2024	0	-32	N/A	N/A	2
3/31/2024	0	-34	-18	-17	N/A
12/31/2023	0	-36	-27	-27	N/A
9/30/2023	0	-38	-28	-28	N/A
6/30/2023	0	-42	-29	-29	N/A
3/31/2023	0	-43	-31	-30	N/A
12/31/2022	0	-44	-35	-35	N/A
9/30/2022	0	-47	-38	-37	N/A
6/30/2022	0	-46	-38	-37	N/A
3/31/2022	0	-41	-36	-34	N/A
12/31/2021	0	-35	-33	-32	N/A
9/30/2021	0	-28	-27	-27	N/A
6/30/2021	0	-23	-22	-21	N/A
3/31/2021	0	-22	-19	-19	N/A
12/31/2020	0	-20	-17	-17	N/A
12/31/2019	0	-17	-19	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SERA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SERA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SERA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SERADie Einnahmen des Unternehmens (95.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: SERADie Einnahmen des Unternehmens (95.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SERA in 3 Jahren voraussichtlich hoch sein wird

Sera Prognostics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Consensus revenue estimates decrease by 14%, EPS upgraded

Consensus revenue estimates decrease by 55%, EPS upgraded

Price target decreased to US$7.00

Consensus forecasts updated

Recent updates

Chief Data Officer recently sold US$86k worth of stock

First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.34 loss in 1Q 2023)

Sera Prognostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Sera Prognostics, Inc., Annual General Meeting, Jun 06, 2024

Chief Scientific Officer notifies of intention to sell stock

President recently sold US$364k worth of stock

Sera Prognostics' PreTRM: A Speculative Buy In Women's Health

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Sera Prognostics, Inc. to Report Q4, 2023 Results on Mar 20, 2024

President recently sold US$225k worth of stock

Sera Prognostics: The Pregnancy Company On A Hot Streak

Independent Chairman notifies of intention to sell stock

General Counsel recently sold US$52k worth of stock

New major risk - Share price stability

Sera Prognostics Inc. Announces Preliminary Efficacy Met in Pivotal Prime Study Interim Look - Enrollment to Stop Due to Success

Consensus revenue estimates decrease by 14%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sera Prognostics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 55%, EPS upgraded

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Sera Prognostics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Market cap size

We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth

Sera Prognostics, Inc. Announces Resignation of Nadia Altomare from the Position of Chief Commercial Officer of the Company, Effective as of June 9, 2023

Sera Prognostics, Inc. Announces Board Changes

First quarter 2023 earnings: EPS exceeds analyst expectations

Full year 2022 earnings: Revenues miss analyst expectations

Sera Prognostics, Inc. Announces Positive Top-Line Data from AVERT PRETERM TRIAL

We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate

Sera Prognostics, Inc. Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the Pretrm® Test-And-Treat Strategy Across Diverse Populations

Insufficient new directors

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Sera Prognostics, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$7.00

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Sera Prognostics, Inc. to Report Q2, 2022 Results on Aug 10, 2022

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Chief Scientific Officer notifies of intention to sell stock

Sera Prognostics Appoints Jane Barlow to Nominating and Governance Committee

Sera Prognostics, Inc.(NasdaqGM:SERA) dropped from Russell 2500 Value Index

Sera Prognostics, Inc. Announces Publication of Data Demonstrating Improved Performance of its PreTRM Test with More Precise Gestational Age

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Sera Prognostics, Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Sera Prognostics, Inc., Annual General Meeting, Jun 03, 2022

Sera Prognostics, Inc Appoints Jane F. Barlow as Director to the Board to Serve as Class I Director

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Scientific Officer exercised options to buy US$282k worth of stock.

Insufficient new directors

We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Sera Prognostics Inc. Announces Pricing for PreTRM® Test, the Only Broadly Validated Blood Test to Assess Risk of Preterm Birth

Third quarter 2021 earnings released: US$0.39 loss per share

Sera Prognostics, Inc. Announces Publication of Health Economic Analysis Supporting Pretrm Test-And-Treat Strategy to Improve Maternal and Infant Health

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken